Evaluation of the Severity of Right to Left Shunt in PFO Patients After Systemic Embolism
Primary Purpose
Patent Foramen Ovale, Embolism
Status
Recruiting
Phase
Not Applicable
Locations
Czechia
Study Type
Interventional
Intervention
Cardiac flow measurement
Sponsored by
About this trial
This is an interventional diagnostic trial for Patent Foramen Ovale focused on measuring Patent foramen ovale, Systemic Embolism, Cardiac Shunt, Right to left shunt, Hemodynamics
Eligibility Criteria
Inclusion Criteria:
- Male and female patients aged ≥18 and < 60 years
- Cryptogenic stroke or Systemic embolization due to paradoxical embolization via Patent Foramen Ovale
- The patient indicated for occlusion of PFO with catheter occluder
Exclusion Criteria:
- Inability to perform spiroergometry
- Inability to perform Transesophageal echocardiography (TEE)
- Inability to perform proper Valsalva maneuver
- Inability to understand and/or signed informed consent form
- Contraindication of Patent Foramen Ovale occlusion by any medical reason or patient refusal
Sites / Locations
- Fakultní nemocnice Brno
- I. interní kardioangiologická klinika, Fakultní nemocnice Hradec KrálovéRecruiting
- Fakultní nemocnice Ostrava
- Nemocnice Na Homolce
- Všeobecná fakultní nemocnice v Praze
- Institut klinické a experimentální medicíny (IKEM)Recruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Standard
Arm Description
Subjects indicated for patent foramen ovale closure to prevent a relapse of systemic embolism
Outcomes
Primary Outcome Measures
Quantification of R-L shunt namely
Right-to Left shunt will be measured and quantified using by the novel system for measurement of Cardiac flow- Inntherm. We will obtain these hemodynamics parameters: Systemic blood flow (SBF) pulmonary blood (PBF) Cardiac index (CI), ration of QP/QS. Right to left shunt will be quantified in liters per minutes as well as % of SBF and % of PBF.
We will evaluate R-L shunt in normal conditions as well as after inducible Valsalva maneuver.
Each patient will fill EQ-5D at the beginning of the study and Then 24 weeks after PFO closure.
Transesophageal Echocardiography examination before Patent foramen ovale closure
To evaluate the morphology of atrial septum
Evaluation of the severity of Right-Left shunt and comparison with atrial septal morphology
Is there a significant correlation between atrial septal morphology and the level of severity of cardiac shunt as a predictive factor for systemic embolism
Spiroergometric examination with the measurement of VO2max
Detection of possible desaturation using the spiroergometric examination
Spiroergometric examination with the measurement of SpO2
Detection of possible desaturation using the spiroergometric examination
Transesophageal Echocardiography routine examination after 6 months after Patent foramen ovale closure
To evaluate results 6 months after Patent foramen ovale closure by means of a Patent foramen ovale occluder with a routine examination of Transesophageal Echocardiography
Influence of significant R-L shunt on exercise tolerance and quality of life of the patient
To judge if the closure of Patent foramen ovale especially by the group of patients with significant R-L shunt may influence exercise tolerance and quality of patient life. Precise results of quantification of R-L Shunt will significantly correlated with a possible complications of PFO - systemic embolization, desaturation syndromes.
Secondary Outcome Measures
Full Information
NCT ID
NCT04610463
First Posted
June 12, 2020
Last Updated
October 29, 2020
Sponsor
University Hospital Hradec Kralove
1. Study Identification
Unique Protocol Identification Number
NCT04610463
Brief Title
Evaluation of the Severity of Right to Left Shunt in PFO Patients After Systemic Embolism
Official Title
Evaluation of the Severity of Right to Left Shunt in Patent Foraneb Ovale Patients After Systemic Embolism
Study Type
Interventional
2. Study Status
Record Verification Date
October 2020
Overall Recruitment Status
Recruiting
Study Start Date
September 25, 2020 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital Hradec Kralove
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of the project is to identify new risk indicators of PFO. The evaluation of the R-L shunt is based on the newly developed precise measurement technique. Moreover, this measurement of R-L shunt is feasible in a case when R-L shunt is present only intermittently. Multicentric study with 150 patients.
Detailed Description
The aim of the proposed project is to identify new risk indicators of PFO. The evaluation of the R-L shunt is based on the newly developed precise measurement technique. Moreover, this measurement of R-L shunt is feasible in a case when R-L shunt is present only intermittently.
Detection and quantification of R-L shunt will be realized by the original INNTHERM® ® system (Innova Medical s.r.o., Velká Dobrá). This system is based on the principle of thermodilution.
The basic assumption of our study is the hypothesis, that the size of the R-L shunt (and especially its maximum size during intra-abdominal pressure increase) is a risk factor for the development of paradoxical embolism (from pulmonary to systemic circulation). The most critical consequence of paradoxical embolism is the development of ischemic stroke.
Such measurement with an unequivocal accuracy has never been done so far, due a lack of technology precise enough.
Precise quantification of R-L shunt will allow a more accurate prediction of high-risk patients, especially after correlation with commonly used methods. PFO is now an indication for implantation of percutaneous occlusion device only in case of secondary prevention of stroke, i.e. in a group of patients who have had an ischemic stroke.
Prospectively, precise and better identification of a risk group of these patients could lead to cost reduction of treatment. This cost reduction is crucial for young working-age patients who can be treated before a major irreversible brain injury occurs.
A parameter applicable in primary prevention saves the cost of ischemic stroke treatment and other systemic embolism; additionally it will contribute to cost reduction during aftercare treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Patent Foramen Ovale, Embolism
Keywords
Patent foramen ovale, Systemic Embolism, Cardiac Shunt, Right to left shunt, Hemodynamics
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
150 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Standard
Arm Type
Other
Arm Description
Subjects indicated for patent foramen ovale closure to prevent a relapse of systemic embolism
Intervention Type
Diagnostic Test
Intervention Name(s)
Cardiac flow measurement
Intervention Description
Catheterized hemodynamics evaluation - a measurement of systemic flow and pulmonary flow, R-L shunt, L-R shunt using the INNTHERM® system, prior to PFO closure using a common PFO-occluder (within one catheterization intervention).
Primary Outcome Measure Information:
Title
Quantification of R-L shunt namely
Description
Right-to Left shunt will be measured and quantified using by the novel system for measurement of Cardiac flow- Inntherm. We will obtain these hemodynamics parameters: Systemic blood flow (SBF) pulmonary blood (PBF) Cardiac index (CI), ration of QP/QS. Right to left shunt will be quantified in liters per minutes as well as % of SBF and % of PBF.
We will evaluate R-L shunt in normal conditions as well as after inducible Valsalva maneuver.
Each patient will fill EQ-5D at the beginning of the study and Then 24 weeks after PFO closure.
Time Frame
Up to 24 weeks
Title
Transesophageal Echocardiography examination before Patent foramen ovale closure
Description
To evaluate the morphology of atrial septum
Time Frame
Up to 24 weeks (Prior subject's Patent foramen ovale closure)
Title
Evaluation of the severity of Right-Left shunt and comparison with atrial septal morphology
Description
Is there a significant correlation between atrial septal morphology and the level of severity of cardiac shunt as a predictive factor for systemic embolism
Time Frame
Up to 24 weeks
Title
Spiroergometric examination with the measurement of VO2max
Description
Detection of possible desaturation using the spiroergometric examination
Time Frame
6 months after Patent foramen ovale closure by means of a Patent foramen ovale occluder
Title
Spiroergometric examination with the measurement of SpO2
Description
Detection of possible desaturation using the spiroergometric examination
Time Frame
6 months after Patent foramen ovale closure by means of a Patent foramen ovale occluder
Title
Transesophageal Echocardiography routine examination after 6 months after Patent foramen ovale closure
Description
To evaluate results 6 months after Patent foramen ovale closure by means of a Patent foramen ovale occluder with a routine examination of Transesophageal Echocardiography
Time Frame
Up to 24 weeks
Title
Influence of significant R-L shunt on exercise tolerance and quality of life of the patient
Description
To judge if the closure of Patent foramen ovale especially by the group of patients with significant R-L shunt may influence exercise tolerance and quality of patient life. Precise results of quantification of R-L Shunt will significantly correlated with a possible complications of PFO - systemic embolization, desaturation syndromes.
Time Frame
Up to 24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female patients aged ≥18 and < 60 years
Cryptogenic stroke or Systemic embolization due to paradoxical embolization via Patent Foramen Ovale
The patient indicated for occlusion of PFO with catheter occluder
Exclusion Criteria:
Inability to perform spiroergometry
Inability to perform Transesophageal echocardiography (TEE)
Inability to perform proper Valsalva maneuver
Inability to understand and/or signed informed consent form
Contraindication of Patent Foramen Ovale occlusion by any medical reason or patient refusal
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Josef Šťásek
Phone
+420495832248
Email
josef.stasek@fnhk.cz
First Name & Middle Initial & Last Name or Official Title & Degree
Johana Krempová
Phone
+420601087319
Email
johana.krempova@fnhk.cz
Facility Information:
Facility Name
Fakultní nemocnice Brno
City
Brno
ZIP/Postal Code
62500
Country
Czechia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Poloczek
Phone
+420532232458
Email
martin.poloczek@fnbrno.cz
First Name & Middle Initial & Last Name & Degree
Martin Poloczek
Facility Name
I. interní kardioangiologická klinika, Fakultní nemocnice Hradec Králové
City
Hradec Králové
ZIP/Postal Code
50005
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Josef Šťásek
Phone
+420495832248
Email
josef.stasek@fnhk.cz
First Name & Middle Initial & Last Name & Degree
Josef Šťásek
Facility Name
Fakultní nemocnice Ostrava
City
Ostrava
ZIP/Postal Code
70852
Country
Czechia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marian Branny
Phone
+420 597 374 024
Email
marian.branny@fno.cz
First Name & Middle Initial & Last Name & Degree
Marian Branny
Facility Name
Nemocnice Na Homolce
City
Praga
ZIP/Postal Code
15030
Country
Czechia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Mates
Phone
+420 257 272 213
Email
martin.mates@homolka.cz
First Name & Middle Initial & Last Name & Degree
Martin Mates
Facility Name
Všeobecná fakultní nemocnice v Praze
City
Praha
ZIP/Postal Code
12808
Country
Czechia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tomáš Kovárník
Phone
+420 224 96 2687
Email
Tomas.Kovarnik@vfn.cz
First Name & Middle Initial & Last Name & Degree
Tomáš Kovárník
Facility Name
Institut klinické a experimentální medicíny (IKEM)
City
Praha
ZIP/Postal Code
14021
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Želízko
Phone
+420 236 055 113
Email
michael.zelizko@ikem.cz
First Name & Middle Initial & Last Name & Degree
Michael Želízko
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Evaluation of the Severity of Right to Left Shunt in PFO Patients After Systemic Embolism
We'll reach out to this number within 24 hrs